Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

ClinicalTrials.gov ID: NCT02031640

Public ClinicalTrials.gov record NCT02031640. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.

Study identification

NCT ID
NCT02031640
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
1,113 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2013
Primary completion
Oct 31, 2014
Completion
Nov 30, 2014
Last update posted
Nov 8, 2021

2013 – 2014

United States locations

U.S. sites
94
U.S. states
28
U.S. cities
80
Facility City State ZIP Site status
Teva Investigational Site 10851 Costa Mesa California
Teva Investigational Site 10849 Huntington Beach California
Teva Investigational Site 10872 Huntington Beach California
Teva Investigational Site 10833 Long Beach California
Teva Investigational Site 10861 Los Angeles California
Teva Investigational Site 10798 Mission Viejo California
Teva Investigational Site 10806 Orange California
Teva Investigational Site 10828 Orange California
Teva Investigational Site 10860 Paramount California
Teva Investigational Site 10813 Rancho Mirage California
Teva Investigational Site 10843 Riverside California
Teva Investigational Site 10857 Rolling Hills Estates California
Teva Investigational Site 10847 San Diego California
Teva Investigational Site 10871 San Diego California
Teva Investigational Site 10876 San Jose California
Teva Investigational Site 12270 Walnut Creek California
Teva Investigational Site 12266 Centennial Colorado
Teva Investigational Site 10838 Colorado Springs Colorado
Teva Investigational Site 10844 Denver Colorado
Teva Investigational Site 10799 Wheat Ridge Colorado
Teva Investigational Site 10826 Aventura Florida
Teva Investigational Site 10877 Clearwater Florida
Teva Investigational Site 10816 Edgewater Florida
Teva Investigational Site 12268 Melbourne Florida
Teva Investigational Site 10807 Miami Florida
Teva Investigational Site 10840 Miami Florida
Teva Investigational Site 12269 Miami Florida
Teva Investigational Site 10875 Sarasota Florida
Teva Investigational Site 10855 Tallahassee Florida
Teva Investigational Site 10864 Tampa Florida
Teva Investigational Site 10858 Albany Georgia
Teva Investigational Site 10862 Lawrenceville Georgia
Teva Investigational Site 10848 Savannah Georgia
Teva Investigational Site 10829 River Forest Illinois
Teva Investigational Site 10809 Indianapolis Indiana
Teva Investigational Site 10795 Iowa City Iowa
Teva Investigational Site 10870 Owensboro Kentucky
Teva Investigational Site 10832 Baltimore Maryland
Teva Investigational Site 10850 Bethesda Maryland
Teva Investigational Site 10873 Wheaton Maryland
Teva Investigational Site 12272 White Marsh Maryland
Teva Investigational Site 10834 North Dartmouth Massachusetts
Teva Investigational Site 10815 Minneapolis Minnesota
Teva Investigational Site 10821 Minneapolis Minnesota
Teva Investigational Site 10869 Columbia Missouri
Teva Investigational Site 10868 Rolla Missouri
Teva Investigational Site 10867 St Louis Missouri
Teva Investigational Site 12271 St Louis Missouri
Teva Investigational Site 10827 Warrensburg Missouri
Teva Investigational Site 12261 Missoula Montana
Teva Investigational Site 10794 Bellevue Nebraska
Teva Investigational Site 10814 Bellevue Nebraska
Teva Investigational Site 10846 Brick New Jersey
Teva Investigational Site 10817 Marlton New Jersey
Teva Investigational Site 10856 Ocean City New Jersey
Teva Investigational Site 10845 Skillman New Jersey
Teva Investigational Site 10801 Rochester New York
Teva Investigational Site 10842 Canton Ohio
Teva Investigational Site 10792 Cincinnati Ohio
Teva Investigational Site 10811 Cincinnati Ohio
Teva Investigational Site 10874 Sylvania Ohio
Teva Investigational Site 12265 Toledo Ohio
Teva Investigational Site 10800 Oklahoma City Oklahoma
Teva Investigational Site 10853 Oklahoma City Oklahoma
Teva Investigational Site 10865 Oklahoma City Oklahoma
Teva Investigational Site 12796 Oklahoma City Oklahoma
Teva Investigational Site 10818 Tulsa Oklahoma
Teva Investigational Site 10822 Eugene Oregon
Teva Investigational Site 10791 Lake Oswego Oregon
Teva Investigational Site 10824 Medford Oregon
Teva Investigational Site 10835 Portland Oregon
Teva Investigational Site 10859 Philadelphia Pennsylvania
Teva Investigational Site 12795 Warwick Rhode Island
Teva Investigational Site 10837 North Charleston South Carolina
Teva Investigational Site 12262 Orangeburg South Carolina
Teva Investigational Site 10803 Knoxville Tennessee
Teva Investigational Site 10820 Austin Texas
Teva Investigational Site 10808 Boerne Texas
Teva Investigational Site 10830 Dallas Texas
Teva Investigational Site 10831 El Paso Texas
Teva Investigational Site 10878 Live Oak Texas
Teva Investigational Site 10810 Plano Texas
Teva Investigational Site 10797 San Antonio Texas
Teva Investigational Site 10812 San Antonio Texas
Teva Investigational Site 10793 Sugar Land Texas
Teva Investigational Site 10790 Waco Texas
Teva Investigational Site 10823 South Burlington Vermont
Teva Investigational Site 10796 Richmond Virginia
Teva Investigational Site 10854 Richmond Virginia
Teva Investigational Site 10805 Bellingham Washington
Teva Investigational Site 10866 Seattle Washington
Teva Investigational Site 12264 Tacoma Washington
Teva Investigational Site 10863 Greenfield Wisconsin
Teva Investigational Site 10836 Madison Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02031640, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02031640 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →